Spoiler:
在本帖的末尾，您有机会赢取积分！
开心的星期一， mooer们欢迎回来！ Weekly Buzz在这里，我们根据moomoo平台上上周搜索和信息量选定的热门股票，回顾新闻、表现和社区情绪！（小市值股票不在讨论范围内。）
第一部分：做出你的选择
第二部分：热门股票清单与mooer们的评论
三大指数走势 上涨，罗素2000指数增加 4.57...

辉瑞-BioNTech COVID-19疫苗获得16岁及以上人群的全面FDA批准，可能会提振投资者对股票的信心 $辉瑞 (PFE.US)$和 $BioNTech (BNTX.US)$ as it can lead to more people taking the vaccine. Pfizer-BioNTech enjoys a first mover advantage as its MRNA vaccine was the first to be issued EUA by FDA. With booster shots being advocated and more companies requiring their employees to be vaccinated, it can only mean more revenue.
Moderna is close behind as the second vaccine to receive the EUA from FDA. It has just completed submission to FDA tor full approval of the vaccine for age 18 and older. The stock price of $Moderna (MRNA.US)$ has rallied a lot recently due to it joining S&P 500 $标普500ETF-SPDR (SPY.US)$ so it remains to be seen whether it can still make new highs.
For the other vaccine stocks, the prospects may be less clear. As more countries try to develop their own local vaccines, the competition will become stiffer and the number of potential buyers may decrease.
The Oxford vaccine licensed by $阿斯利康 (AZN.US)$ has been mired in a number of controversies and it has yet to receive EUA from the FDA. There is word the company is reviewing the long term sustainability of the COVID-19 vaccine business.
$诺瓦瓦克斯医药 (NVAX.US)$ has received much interest in its non-MRNA vaccine but until it is rolled out, there may still be unknowns with regards to its performance and safety.
最后但并非最不重要的是，需要注意的是，医药商业不仅仅局限于COVID-19疫苗，因此股票价格可能会受非疫苗相关发展的影响。
免责声明： 以上内容不构成财务建议，不应视为投资建议。在做出任何投资决策之前，请进行尽职调查并请教您的财务顾问。
如果您喜欢阅读本文，您可能还对以下内容感兴趣
“加州直播”和Aapl的短期展望 https://www.moomoo.com/zh-cn/community/feed/106924953829382?lang_code=2
最高回报到目前为止 https://www.moomoo.com/zh-cn/community/feed/106911175344134?lang_code=2
优秀的CEO：Tim Cook和Steve Jobs https://www.moomoo.com/zh-cn/community/feed/106837029355526?lang_code=2